L-ASPARAGINASE INDUCED HYPOFIBRINOGENEMIA: A CASE REPORT

Authors

  • Balaji O Post graduate , Department of Pharmacology, Kasturba Medical college , Manipal university , Manipal.
  • Amita d Post graduate , Department of Pharmacology, Kasturba Medical college , Manipal university , Manipal.
  • Navin P Assistant professor, Department of Pharmacology, Kasturba Medical college , Manipal university , Manipal.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i5.17320

Keywords:

L-asparaginase, Hypofibrinogenemia, Adverse effect, Leukemia

Abstract

Anticancer therapy is always known to cause various side effects. L-asparaginase used in the treatment of adult T-cell lymphoblastic leukemia is a
novel class of drug, an enzyme produced from plants as well as microorganisms except human. It is known to cause various adverse reactions including life-threatening neurological complications and thrombotic disorders. Hence, we report a case of hypofibrinogenemia associated with L-asparaginase in a patient treated for T-cell adult lymphoblastic leukemia.

 

Downloads

Download data is not yet available.

References

Thandeeswaran M, Mahendran R, Kiran K, Nawa K, Palaniswamy M, Jayaraman A. Screening and production of anticarcinogenic enzyme from Escherichia coli CTLS20: L - Asparaginase. Int J Pharm Pharm Sci 2016;8(3):244-8.

Kumar R, Sedolkar V, Triveni A, Kumar M, Shivannavar C, Gaddad S. Isolation, screening and characterization of L-asparaginase producing fungi from medicinal plants. Int J Pharm Pharm Sci 2015;8(1):281-3.

Batool T, Makky EA, Jalal M, Yusoff MM. A comprehensive review on L-asparaginase and its applications. Appl Biochem Biotechnol 2016;178(5):900-23.

Bolton-Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, et al. The rare coagulation disorders - Review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia 2004;10(5):593-628.

Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Haematol 2001;114(2):249-57.

Besser MW, MacDonald SG. Acquired hypofibrinogenemia: Current perspectives. J Blood Med 2016;7:217-25.

Bettigole RE, Himelstein ES, Oettgen HF, Clifford GO. Hypofibrinogenemia due to L-asparaginase: Studies of fibrinogen survival using autologous 131-I-fibrinogen. Blood 1970;35(2):195-200.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49(9):2229-32.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27(6):538.

Published

01-05-2017

How to Cite

O, B., Amita d, and N. P. “L-ASPARAGINASE INDUCED HYPOFIBRINOGENEMIA: A CASE REPORT”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 5, May 2017, pp. 11-12, doi:10.22159/ajpcr.2017.v10i5.17320.

Issue

Section

Case Study(s)